Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals

What Was Tested

Researchers studied Glucagon in this randomized controlled trial publication.

This study sought to examine whether enhanced hepatic sensitivity to glucagon contributes to impaired glucose homeostasis in subjects with type 2 diabetes mellitus (T2DM).

Why It Was Studied

Eight T2DM and 9 age-, weight-, and gender-matched nondiabetic subjects received a 4-hour glucagon infusion at the rates of 0.2, 0.5, 2, 6, and 8 ng. kg(-1). min(-1) while maintaining the plasma insulin concentration constant at the basal level with exogenous infusions of somatostatin and insulin.

Each glucagon infusion study was performed on a separate day and in random order. 3-(3)H-glucose was infused in all studies to measure endogenous glucose production (EGP) and the rate of whole body glucose disposal.

Who Took Part

The age groups tagged for this paper are middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Eight T2DM and 9 age-, weight-, and gender-matched nondiabetic subjects received a 4-hour glucagon infusion at the rates of 0.2, 0.5, 2, 6, and 8 ng. kg(-1). min(-1) while maintaining the plasma insulin concentration constant at the basal level with exogenous infusions of somatostatin and insulin.

Each glucagon infusion study was performed on a separate day and in random order. 3-(3)H-glucose was infused in all studies to measure endogenous glucose production (EGP) and the rate of whole body glucose disposal.

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Fatty Acids, Nonesterified, Glucagon, Glucose, Hormones, Lactic Acid and Liver.

What This Means in Plain Language

The paper is a randomized study of Glucagon.

The publication is from 2002 (Metabolism: clinical and experimental), a journal based in United States.

More context: the Glucagon compound page, all human trials.